Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > a lot of volume again
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(99)
•••
Comment by Aarcoron Apr 08, 2022 12:48pm
98 Views
Post# 34588319

RE:RE:RE:a lot of volume again

RE:RE:RE:a lot of volume again
KayakerBC wrote: FTR got into the stock depending too much on other people's opinions. Instead of taking responsibility for his investment decisions (as grownups do),  he blames others. He's immature and bitter and is trying to take revenge on those he thinks are responsible for his losses.


I invested in this company and continued to invest in this company because management has repeatedly indicated they planned to go clinical with xb3.  This has never happened and there is no indication it ever will.  Multiple broken promises and changes in course.  So now I am left holding the bag because management has not delivered.  You can be sure that the responsibility of those failures lies with management and management alone.  I view anyone supporting this incompetent management and BoD as part of the problem.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities